KOL Perspectives: Mid-to-Late Stage Pipeline Therapies in Lupus
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
› The briefing includes analysis of KOL opinion on the following topic areas:
– Development of Lupuzor for SLE
– Lupuzor’s Phase III trial design
– Lupuzor’s Phase IIb efficacy data in SLE
– Anticipated future use of Lupuzor in SLE
– Development of baricitinib in SLE
– Endpoints used in baricitinib’s Phase II trial
– Expectations for baricitinib’s Phase II trial results
– Views on the increased risk of thromboembolic events seen with baricitinib in RA
– Views on the risk of thromboembolic events in the lupus patient population
– Concerns regarding herpes zoster in lupus patients
– Impact of high infection rate with JAK inhibitor use in RA, on anticipated baricitinib use in SLE
– Development of IFN kinoid in SLE
– IFNα kinoid vs. anifrolumab in SLE
Scope
› The insight briefing is based on Sociable Pharma’s analysis of primary research with our lupus key opinion leaders (KOLs)
› In total, we conducted interviews with 14 KOLs:
– Seven Europe-based & seven US-based
– Interviews performed in December 2017
> KOL data is analyzed to produce:
– Charts summarizing KOL opinions
– Chart call-outs of key information & details
– KOL quotes
– Summary of KOL reporting trends
– Insight from Sociable Pharma's analysts
Key Highlights
Most KOLs flagged the need for more data to understand Lupuzor’s mechanism of action and elucidate its efficacy in lupus patients
KOLs were divided over Lupuzor’s efficacy in lupus based on its Phase IIb data, with some highlighting that it may be comparable to belimumab
Most KOLs had a positive opinion regarding baricitinib’s development in lupus, based on its data in other indications
Reasons to Buy
Combines Qualitative & semi-quantitative insight from key opinion leaders on " Mid-to-Late Stage Pipeline Therapies in Lupus "
Includes insight & recommendations from our disease-specific healthcare analysts
Utilizes independent expert viewpoints to validate the impact of new clinical data & emerging trends on management of Lupus
Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion
AstraZeneca
Lilly
Table of Contents
Frequently asked questions
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.